4-propoxybutanoic acid | 41639-57-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-propoxybutanoic acid
• 英文别名: 4-propoxy-butyric acid；4-Propyloxy-buttersaeure；4-Propoxy-buttersaeure；4-Propoxybuttersaeure；Butanoic acid, 4-propoxy-
• CAS: 41639-57-0
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: IWPPWTPACQFMLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  246.0±23.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-propoxybutanoic acid 在 正丁基锂 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成
  参考文献：
  名称：

  Highly potent inhibitors of TNF-α production. Part I

  摘要：

  Discovery of new chemical leads of inhibitors for TNF-alpha production starting from the chemical modification of I is reported. Further biological studies of 1 to disclose the site of its action strongly suggested that 1 inhibits LPS-induced TNF-alpha expression in the liver and spleen of mice. Structure-activity relationships (SARs) are also discussed and full details including the chemistry are reported. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00381-4
• 作为产物：
  描述：

  n-Propyl 4-n-propoxybutanoate 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-propoxybutanoic acid
  参考文献：
  名称：

  Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

  摘要：

  具有通式（I）的一种化合物： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，其中： Q选自以下群组： 和 L选自以下群组： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，可用于治疗代谢综合征和血脂异常等疾病、疾患或症状。

  公开号：

  US20060264489A1

文献信息

• Methods for inhibiting uterine fibrosis
  申请人：ELI LILLY AND COMPANY

  公开号：EP0650724A1

  公开（公告）日：1995-05-03

  A method of inhibiting uterine fibrosis comprising administering to a human in need of treatment an effective amount of a compound having the formula    wherein R is hydrogen; hydroxy; C₁-C₆ alkoxy; a group of the formula -O-C(O)-Ra, wherein Ra is hydrogen, C₁-C₆ alkyl optionally substituted with amino, halo, carbonyl, C₁-C₆ alkoxycarbonyl, C₁-C₇ alkanoyloxy, carbamoyl and/or aryl; or Ra is C₁-C₆ alkenyl optionally substituted with aryl; or Ra is a C₃-C₇ cycloalkyl; or Ra is aryl optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, and/or halo; or Ra is -O-aryl, said aryl optionally substituted with hydroxy C₁-C₆ alkyl, C₁-C₆ alkoxy, and/or halo,    or R is a group of the formula -O-SO₂-Rb wherein Rb may be C₁-C₆ alkyl or aryl optionally substituted with C₁-C₆ alkyl;    or R is carbamoyloxy wherein the nitrogen may be substituted once or twice with C₁-C₆ alkyl;    or R is a group of the formula -O-C(O)Rc-O-(C₁-C₆ alkyl) wherein Rc is a bond or C₁-C₆ alkanediyl;    R¹ is halo, C₁-C₆ alkyl, C₁-C₇ alkyl substituted with C₁-C₆ alkyl, substituted or unsubstituted C₃-C₇ cycloalkyl, or substituted or unsubstituted C₃-C₇ cycloalkenyl;    R² is O or CH₂;    R³ is CH₂ or (CH₂)₂;    R⁴ is CH₂, or a bond; and    R⁵ is amino, nitrilo optionally substituted once or twice with C₁-C₆ alkyl; or an N-heterocyclic ring which optionally has another hetero atom selected from N, O, or S in said ring; or a pharmaceutically acceptable salt or solvate thereof.

  抑制子宫纤维化的方法包括向需要治疗的人类施用具有以下式子的化合物的有效量： 其中，R为氢、羟基、C₁-C₆烷氧基、式子-O-C（O）-Ra的基团，其中Ra为氢、C₁-C₆烷基，该烷基可选地带有氨基、卤素、羰基、C₁-C₆烷氧羰基、C₁-C₇烷酰氧基、氨基甲酰基和/或芳基；或Ra为可选地带有芳基的C₁-C₆烯基；或Ra为C₃-C₇环烷基；或Ra为可选地带有羟基、C₁-C₆烷基、C₁-C₆烷氧基和/或卤素的芳基；或Ra为-O-芳基，该芳基可选地带有羟基、C₁-C₆烷基、C₁-C₆烷氧基和/或卤素，或R为式子-O-SO₂-Rb的基团，其中Rb可以是C₁-C₆烷基或可选地带有C₁-C₆烷基的芳基；或R为氨基甲酰氧基，其中氮原子可以被C₁-C₆烷基取代一次或两次；或R为式子-O-C（O）Rc-O-（C₁-C₆烷基）的基团，其中Rc为键或C₁-C₆烷二基；R¹为卤素、C₁-C₆烷基、可带有C₁-C₆烷基的C₁-C₇烷基、取代或未取代的C₃-C₇环烷基，或取代或未取代的C₃-C₇环烯基；R²为O或CH₂；R³为CH₂或（CH₂）₂；R⁴为CH₂或键；R⁵为氨基、一次或两次可选地取代C₁-C₆烷基的硝基基或在该环中可选地具有另一种来自N、O或S的杂原子的N-杂环环；或其药学上可接受的盐或溶剂化物。
• Methods for inhibiting bone loss
  申请人：ELI LILLY AND COMPANY

  公开号：EP0651998A1

  公开（公告）日：1995-05-10

  A method of inhibiting bone loss comprising administering to a human in need of treatment an effective amount of a compound having the formula    wherein R is hydrogen; hydroxy; C₁-C₆ alkoxy; a group of the formula -O-C(O)-Ra, wherein Ra is hydrogen, C₁-C₆ alkyl optionally substituted with amino, halo, carbonyl, C₁-C₆ alkoxycarbonyl, C₁-C₇ alkanoyloxy, carbamoyl and/or aryl; or Ra is C₁-C₆ alkenyl optionally substituted with aryl; or Ra is a C₃-C₇ cycloalkyl; or Ra is aryl optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, and/or halo; or Ra is -O-aryl, said aryl optionally substituted with hydroxy C₁-C₆ alkyl, C₁-C₆ alkoxy, and/or halo,    or R is a group of the formula -O-SO₂-Rb wherein Rb may be C₁-C₆ alkyl or aryl optionally substituted with C₁-C₆ alkyl;    or R is carbamoyloxy wherein the nitrogen may be substituted once or twice with C₁-C₆ alkyl;    or R is a group of the formula -O-C(O)Rc-O-(C₁-C₆ alkyl) wherein Rc is a bond or C₁-C₆ alkanediyl;    R¹ is halo, C₁-C₆ alkyl, C₁-C₇ alkyl substituted with C₁-C₆ alkyl, substituted or unsubstituted C₃-C₇ cycloalkyl, or substituted or unsubstituted C₃-C₇ cycloalkenyl;    R² is O or CH₂;    R³ is CH₂ or (CH₂)₂;    R⁴ is CH₂, or a bond; and    R⁵ is amino, nitrilo optionally substituted once or twice with C₁-C₆ alkyl; or an N-heterocyclic ring which optionally has another hetero atom selected from N, O, or S in said ring; or a pharmaceutically acceptable salt or solvate thereof.

  一种抑制骨质流失的方法，包括向需要治疗的人体内投与一定量的具有以下式子的化合物：其中R为氢；羟基；C₁-C₆烷氧基；式子-O-C(O)-Ra的基团，其中Ra为氢，C₁-C₆烷基，可选地被氨基，卤素，羰基，C₁-C₆烷氧羰基，C₁-C₇脂肪酰氧基，氨基甲酰和/或芳基取代；或Ra为C₁-C₆烯基，可选地被芳基取代；或Ra为C₃-C₇环烷基；或Ra为芳基，可选地被羟基，C₁-C₆烷基，C₁-C₆烷氧基和/或卤素取代；或Ra为-O-芳基，所述芳基可选地被羟基，C₁-C₆烷基，C₁-C₆烷氧基和/或卤素取代，或R为式子-O-SO₂-Rb的基团，其中Rb可以是C₁-C₆烷基或可选地被C₁-C₆烷基取代的芳基；或R为氨基甲酰氧基，其中氮原子可以被C₁-C₆烷基取代一次或两次；或R为式子-O-C(O)Rc-O-(C₁-C₆烷基)的基团，其中Rc为键或C₁-C₆烷二基；R¹为卤素，C₁-C₆烷基，可选地被C₁-C₆烷基取代的C₁-C₇烷基，取代或未取代的C₃-C₇环烷基，或取代或未取代的C₃-C₇环烯基；R²为O或CH₂；R³为CH₂或(CH₂)₂；R⁴为CH₂或键；R⁵为氨基，一次或两次可选地被C₁-C₆烷基取代的氮甲基，或在所述环中可选地有另一种异原子N、O或S的N-杂环，或其药学上可接受的盐或溶剂。
• Methods for lowering serum cholesterol
  申请人：ELI LILLY AND COMPANY

  公开号：EP0657162A1

  公开（公告）日：1995-06-14

  A method of lowering serum cholesterol levels comprising administering to a human in need of treatment an effective amount of a compound having the formula    wherein R is hydrogen; hydroxy; C₁-C₆ alkoxy; a group of the formula -O-C(O)-Ra, wherein Ra is hydrogen, C₁-C₆ alkyl optionally substituted with amino, halo, carbonyl, C₁-C₆ alkoxycarbonyl, C₁-C₇ alkanoyloxy, carbamoyl and/or aryl; or Ra is C₁-C₆ alkenyl optionally substituted with aryl; or Ra is a C₃-C₇ cycloalkyl; or Ra is aryl optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, and/or halo; or Ra is -O-aryl, said aryl optionally substituted with hydroxy C₁-C₆ alkyl, C₁-C₆ alkoxy, and/or halo,    or R is a group of the formula -O-SO₂-Rb wherein Rb may be C₁-C₆ alkyl or aryl optionally substituted with C₁-C₆ alkyl;    or R is carbamoyloxy wherein the nitrogen may be substituted once or twice with C₁-C₆ alkyl;    or R is a group of the formula -O-C(O)Rc-O-(C₁-C₆ alkyl) wherein Rc is a bond or C₁-C₆ alkanediyl;    R¹ is halo, C₁-C₆ alkyl, C₁-C₇ alkyl substituted with C₁-C₆ alkyl, substituted or unsubstituted C₃-C₇ cycloalkyl, or substituted or unsubstituted C₃-C₇ cycloalkenyl;    R² is O or CH₂;    R³ is CH₂ or (CH₂)₂;    R⁴ is CH₂, or a bond; and    R⁵ is amino, nitrilo optionally substituted once or twice with C₁-C₆ alkyl; or an N-heterocyclic ring which optionally has another hetero atom selected from N, O, or S in said ring; or a pharmaceutically acceptable salt or solvate thereof.

  降低血清胆固醇水平的方法包括向需要治疗的人体内给予具有以下结构式的化合物的有效量：其中R是氢；羟基；C₁-C₆烷氧基；式为-O-C（O）-Ra的基团，其中Ra是氢，C₁-C₆烷基，可选地取代氨基，卤素，羰基，C₁-C₆烷氧羰基，C₁-C₇烷酰氧基，氨基甲酰基和/或芳基；或Ra是C₁-C₆烯基，可选地取代芳基；或Ra是C₃-C₇环烷基；或Ra是芳基，可选地取代羟基，C₁-C₆烷基，C₁-C₆烷氧基和/或卤素；或Ra是-O-芳基，所述芳基可选地取代羟基C₁-C₆烷基，C₁-C₆烷氧基和/或卤素，或R是式为-O-SO₂-Rb的基团，其中Rb可以是C₁-C₆烷基或芳基，可选地取代C₁-C₆烷基；或R是氨基甲氧基，其中氮原子可以被C₁-C₆烷基取代一次或两次；或R是式为-O-C（O）Rc-O-（C₁-C₆烷基）的基团，其中Rc是键或C₁-C₆烷二基基；R¹是卤素，C₁-C₆烷基，C₁-C₇烷基，取代或未取代的C₃-C₇环烷基，或取代或未取代的C₃-C₇环烯基；R²是O或CH₂；R³是CH₂或（CH₂）₂；R⁴是CH₂或键；R⁵是氨基，一次或两次可选地取代C₁-C₆烷基的硝基基团；或在所述环中选择另一个杂原子N、O或S的N-杂环状物；或其药学上可接受的盐或溶剂。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Palani Anandan

  公开号：US20080019978A1

  公开（公告）日：2008-01-24

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）的化合物及其药学上可接受的盐，溶剂化合物，酯和互变异构体，其中： Q选自以下组： L选自以下组： 本发明还提供了包含一种或多种式（I）化合物的药学组合物以及使用式（I）化合物的方法。
• Nitrogen-containing heterocyclic compounds and methods of use thereof
  申请人：Palani Anandan

  公开号：US20070066630A1

  公开（公告）日：2007-03-22

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）化合物及其药学上可接受的盐、溶剂化合物、酯和互变异构体，其中：Q选自以下组：L选自以下组：包括一种或多种式（I）化合物的药学组合物，以及使用式（I）化合物的方法。